Immunogenic epitope for immunotherapy
| Title: | Immunogenic epitope for immunotherapy |
|---|---|
| Patent Number: | 8,080,634 |
| Publication Date: | December 20, 2011 |
| Appl. No: | 12/180045 |
| Application Filed: | July 25, 2008 |
| Abstract: | The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses. |
| Inventors: | Singh, Harpreet (Tubingen, DE); Walter, Steffen (Dusslingen, DE); Weinschenk, Toni (Aichwald, DE); Hilf, Norbert (Kirchentellinsfurt, DE); Schoor, Oliver (Tubingen, DE); Lemmel, Claudia (Wuelfrath, DE) |
| Assignees: | Immatics Biotechnologies GmbH (Tubingen, DE) |
| Claim: | 1. A peptide comprising a sequence SEQ ID NO: 1, wherein said peptide has an overall length of from 8 to 100 amino acids and will induce T cells cross-reacting with said peptide. |
| Claim: | 2. The peptide according to claim 1 , having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II. |
| Claim: | 3. The peptide according to claim 1 , wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 1. |
| Claim: | 4. The peptide according to claim 1 , wherein the peptide includes at least one modification selected from the group consisting of: (a) a non-peptide bond; (b) a reverse peptide bond; (c) a chemical modification at the amino-terminus selected from the group consisting of: a hydrophobic group, an acetyl group, and a 9-fluorenylmethoxy-carbonyl group; (d) a chemical modification at the carboxy-terminus selected from the group consisting of: a hydrophobic group, a t-butyloxycarbonyl group, and an amido group; (e) a chemically modified amino acid side chain; and (f) a D-isomer of an amino acid. |
| Claim: | 5. The peptide according to claim 1 , wherein the peptide is a fusion protein comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). |
| Claim: | 6. An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1 . |
| Claim: | 7. The method according to claim 6 , wherein the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell. |
| Claim: | 8. The method according to claim 6 , wherein the antigen-presenting cell comprises an expression vector capable of expressing said peptide. |
| Claim: | 9. A pharmaceutical composition comprising the peptide of claim 1 . |
| Claim: | 10. The pharmaceutical composition of claim 9 wherein the pharmaceutical composition kills cancer cells. |
| Claim: | 11. The peptide of claim 4 , wherein the peptide is modified at the amino-terminus with a hydrophobic group selected from the group consisting of: a carbobenzoyl group, a dansyl group, and a t-butyloxycarbonyl group. |
| Claim: | 12. The peptide of claim 4 wherein the peptide comprises a chemically modified amino acid side chain, wherein said modification is selected from the group consisting of: (a) acylation, (b) amidination, (c) pyridoxylation of lysine, (d) reductive alkylation, (e) trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS), (f) amide modification of a carboxyl group, (g) sulphydryl modification by performic acid oxidation of cysteine to cysteic acid, (h) formation of mercurial derivatives, (i) formation of mixed disulphides with other thiol compounds, (j) reaction with maleimide, (k) carboxymethylation with iodoacetic acid or iodoacetamide, (l) carbamoylation with cyanate at alkaline pH, (m) selective reduction of a disulfide bond, (n) modification of a glutamic acid residue with Woodward's reagent K, (o) formation of a crosslink between a lysine residue and a glutamic acid residue with N-(3-(dimethylamino)propyl)-N′-ethylcarbodiimide, (p) modification of a histidine residue with diethylpyrocarbonate or 4-hydroxy-2-nonenal, (q) attachment of poly(ethylene)glycol to a lysine residue, (r) modification of a methionine residue with iodoacetamide, bromoethylamine, or chloramine T, (s) modification of a tyrosal residue by tetranitromethane or N-acetylimidazole, (t) formation of a dityrosine cross-link; (u) modification of tryptophan by N-bromosuccinimide, 2-hydroxy-5-nitrobenzyl bromide, or 3-bromo-3-methyl-2-(2-nitrophenylmercapto)-3H-indole, (v) formation of a crosslink by glutaraldehyde, polyethyleneglycol diacrylate, or formaldehyde, (w) modification with polyethylene glycol (PEG); and (x) carbamylation with potassium cyanate. |
| Claim: | 13. The pharmaceutical composition of claim 9 , wherein said composition is formulated for administration to a patient via a route selected from the group consisting of: intravenous injection, sub-cutaneous injection, intradermal injection, intraperitoneal injection, and intramuscular injection. |
| Claim: | 14. The pharmaceutical composition of claim 9 , wherein said composition is formulated for administration to a cell ex vivo. |
| Claim: | 15. The pharmaceutical composition of claim 9 further comprising at least one additional constituent selected from the group consisting of: (a) an adjuvant; (b) a cytokine; (c) a suitable delivery system; and (d) a carrier. |
| Claim: | 16. The pharmaceutical composition of claim 9 , wherein said composition comprises from 2 to 50 peptides derived from a tumor associated antigen. |
| Claim: | 17. The pharmaceutical composition of claim 14 , comprising 50 μg to 1.5 mg of each peptide per dose. |
| Claim: | 18. The pharmaceutical composition of claim 9 , wherein said composition induces an anti-tumor immune response. |
| Claim: | 19. The pharmaceutical composition of claim 18 , wherein said tumor aberrantly expresses a peptide comprising SEQ ID NO: 1. |
| Claim: | 20. The pharmaceutical composition of claim 19 , wherein said tumor is selected from the group consisting of colon carcinoma and lung carcinoma. |
| Current U.S. Class: | 530/328 |
| Patent References Cited: | 6531447 March 2003 Ruben et al. 7396904 July 2008 Weinschenk et al. 2009/0004213 January 2009 Singh et al. 54733 August 2001 59609 August 2002 02078524 October 2002 03000113 January 2003 2004030615 April 2004 2005044990 May 2005 2005116051 December 2005 2007028574 March 2007 |
| Other References: | Essell (J. NIH Res. 1995 7:46). cited by examiner Spitler (Cancer Biotherapy, 1995, 10:1-3). cited by examiner Boon (Adv. Can. Res. 1992 58:177-210). cited by examiner Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4). cited by examiner Dermer (Bio/Technology, 1994, 12:320). cited by examiner Gura (Science, 1997, 278:1041-1042). cited by examiner Jain (Sci. Am., 1994, 271:58-65). cited by examiner Written Opinion of PCT/EP2008/006153 Dated Aug. 21, 2009. cited by other Database Uniprot [Online]: Q4TE80-TETNG, “Full=Chromosome Undertermined SCAF5582, Whole Genome Shotgun Sequence”, Jul. 19, 2005. Whitehead Institute Center for Genome Research. cited by other Database GENESEQP [Online]:ABP64001, Leach, MD et al. “New Polypeptide Designated ORFX are Present in Human Atherogenic Cells and are Useful to Preven and Treat OFRX-associated Disorders Including Cancer, Allergy, Wouldn Healing or Autoimmune, Cardiovascular or Inflammatory Disease” Nov. 4, 2002. cited by other McDevitt H., “Specific antigen vaccination to treat autoimmune disease,” PNAS, Oct. 5, 2004, vol. 101, pp. 14627-14630. cited by other Mihalyo et al., “In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy,” J. Immunol, 2004, pp. 5338-5345. cited by other Oehlen et al., “Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen,” J. Immunol, 2001, pp. 2863-2870. cited by other Adler A., “Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity,” Curr Immunol Rev., Jan. 1, 2005, 1(1) pp. 21-28. cited by other Vella et al., “B cells are not essential for peripheral T-cell tolerance,” Proc. Natl. Acad. Sci, Jan. 1996, vol. 93, pp. 951-955. cited by other Vidard et al., “Specific T-cell tolerance may be preceded by a primary response,” Proc. Natl. Acad. Sci., Jun. 1994, vol. 91, pp. 5627-5631. cited by other Sadovnikova et al., “Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy,” Proc. Natl. Acad. Sci., Nov. 1996, vol. 93, pp. 13114-13118. cited by other Kurts et al., “CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose,” PNAS, Oct. 26, 1999, vol. 96, No. 22, pp. 12703-12707. cited by other Polymenidou et al., “Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection,” PNAS, Oct. 5, 2004, vol. 101, pp. 14670-14676. cited by other Maeda et al., “Suppressor T cells regulate the nonanergic cell population that remains after peripheral tolerance is induced . . . ,” PNAS, Nov. 21, 2000, vol. 97, No. 24, pp. 13257-13262. cited by other “Approved Drugs for Oncology,” Center Watch: Oncology Approved Drug Therapies, retrieved from the WWW on Sep. 10, 2010, pp. 1-8 (http://www.centerwatch.com/drug-information/fda-approvals/drug-areas.aspx? AreaID=12). cited by other A search of the National Institutes of Health's (“NIH”) clinicaltrials.gov website on Aug. 23, 2010 for the terms “cancer” and “peptide vaccine” discloses 74 clinical trials that were first received by the NIH between Jan. 1, 1996 and Jul. 27, 2007, 5 pages. cited by other “FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer,” Dendreon Press Release, Apr. 29, 2010, pp. 1-3. cited by other Data from the NIH's clinicaltrials.gov website, clinical trials for Provenge®, 2001, 5 pages. cited by other Database GENESEQ [Online] Nov. 7, 2001, “Novel Signal Transduction Pathway Protein, SEQ ID 642.” XP002497882 Retrieved From EBI Accession No. GSP: AAU17077 Database Accession No. AAU17077, The Whole Document. cited by other Database UNIPROT [Online] Sep. 13, 2005, “Subname: Full=FERMT1 PROTEI;” XP002497883, Retrieved From EBI Accession No. UNIPROT: Q49AC8, Database Accession No. Q49AC8, The Whole Document. cited by other Database GENESEQ [Online], Sep. 3, 2001, “Human Colon Cancer Antigen Protein SEQ ID No. 6503.” XP002505842, Retrieved From EBI Accession No. GSP: AAG75739, Database Accession No. AAG75739, The Whole Document. cited by other Database UNIPROT [Online], May 1, 2000, “Recname: Full=NADPH Oxidase 1; Short=NOX-1; EC= Database GENESEQ [Online], Jan. 29, 2003, “Human Expressed Protein Tag (EPT) #29.” XP002505843 Retrieved From EBI Accession No. GSP: ABU03249, Database Accesion No. ABU03249 Discloses Sequence 29 of WO02078524. The Whole Document. cited by other Database UNIPROT [Online] Oct. 1, 1989, “Recname: Full=Proliferating Cell Nuclear Antigen; Short=PCNA; Altname: Full=Cyclin;” XP002505844, Retrieved From EBI Accession No. UNIPROT: p12004, Database Accession No. P12004, Comprises Present Sequence 3. The Whole Document. cited by other Database GENESEQ [Online], Nov. 14, 2004, “Tumour-Associated Antigenic Target (TAT) Polypeptide PR080966, SEQ: 1080.” XP002505845, Retrieved From EBI Accession No. GSP: ABM80429. Database Accession No. ABM80429 Discloses Sequence 1080 of WO2004030615. The Whole Document. cited by other Database UNIPROT[Online], Jul. 1, 1993, “Recname: Full-DNA Topoisomerase 2-Beta; EC=Http://SRS.EBI.SC.UK/SRSBIN/CGI-BIN/WGETZ?[Enzyme-ECNumber:5.99.1.3; Altname: Full=DNA Topoisomerase II, Beta Isozyme; XP002505846, Retrieved From EBI Accession No. UNIPROT:Q02880 Database Accession No. Q02880. The Whole Document. cited by other Database UNIPROT [Online], “Recname: Full-DNA Topoisomerase 2-Alpha; EC=Http://SRS.EBI.SC.UK/SRSBIN/CGI-BIN/WGETZ?[Enzyme-ECNumber:5.99.1.3]+-E>5.99.1.3.; Altname: Full=DNA Topoisomerase II, Alpha Isozyme; XP002505847, Retrieved From EBI Accession No. UNIPROT P11388; Database Accession No. P11388. The Whole Document, 1989. cited by other Search Report for PCT/EP2008/006153; Dated Jan. 19, 2009. cited by other |
| Primary Examiner: | Huff, Sheela J |
| Attorney, Agent or Firm: | Baker Donelson Bearman Caldwell & Berkowitz, PC |
| Accession Number: | edspgr.08080634 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|